Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barbui

Showing results (191-200 of 380) with videos related to

Pageof 38
Sort By:
Thrombosis Research|June 1, 1989
Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium saltsA Falanga, E Shaw, M B Donati, et al.
American Journal of Hematology|April 17, 1998
Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathwayS Cortelazzo, M Marchetti, E Orlando, et al.
Leukemia|November 17, 2010
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsA Pardanani, A M Vannucchi, F Passamonti, et al.
Haemostasis|January 1, 1990
Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disordersM Romano, P Viero, S Cortellazzo, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1994
Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemiaA Falanga, F A Ofosu, S Cortelazzo, et al.
Haematologica|January 1, 1972
[Radioisotope study of Hodgkin's desease with special reference to the morphological and functional aspects of the spleen]A Vianello Dri, T Barbui, M Cazzavillan, et al.
British Journal of Cancer|November 1, 1980
Heparin does not modify plasma daunomycin disappearance in acute leukaemia patientsE Piazza, S Cortellazzo, L Ottolenghi, et al.
Thrombosis and Haemostasis|February 25, 1988
Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disordersS Cortelazzo, M Galli, D Castagna, et al.
Leukemia|September 1, 1991
Monoclonal lymphocytosis with villous lymphocytes: a chronic lymphoproliferative disease of CD11c+ B-cellsR Bassan, M G Neonato, M Abbate, et al.
Lancet (London, England)|August 9, 1986
Reduced platelet mitogenic activity in myeloproliferative disordersM Romano, A Poggi, M B Donati, et al.
Pageof 38

Showing results (191-200 of 380) with videos related to

Sort By:
Pageof 38
Thrombosis Research|June 1, 1989
Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium saltsA Falanga, E Shaw, M B Donati, et al.
American Journal of Hematology|April 17, 1998
Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathwayS Cortelazzo, M Marchetti, E Orlando, et al.
Leukemia|November 17, 2010
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsA Pardanani, A M Vannucchi, F Passamonti, et al.
Haemostasis|January 1, 1990
Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disordersM Romano, P Viero, S Cortellazzo, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1994
Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemiaA Falanga, F A Ofosu, S Cortelazzo, et al.
Haematologica|January 1, 1972
[Radioisotope study of Hodgkin's desease with special reference to the morphological and functional aspects of the spleen]A Vianello Dri, T Barbui, M Cazzavillan, et al.
British Journal of Cancer|November 1, 1980
Heparin does not modify plasma daunomycin disappearance in acute leukaemia patientsE Piazza, S Cortellazzo, L Ottolenghi, et al.
Thrombosis and Haemostasis|February 25, 1988
Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disordersS Cortelazzo, M Galli, D Castagna, et al.
Leukemia|September 1, 1991
Monoclonal lymphocytosis with villous lymphocytes: a chronic lymphoproliferative disease of CD11c+ B-cellsR Bassan, M G Neonato, M Abbate, et al.
Lancet (London, England)|August 9, 1986
Reduced platelet mitogenic activity in myeloproliferative disordersM Romano, A Poggi, M B Donati, et al.
Pageof 38